VCYT: the cash flow

MyFinsight

For the quarter ending 2026-03-31, VCYT had -$99,433K decrease in cash & cash equivalents over the period. $32,253K in free cash flow.

Cash Flow Overview

Change in Cash
-$99,433K
Free Cash flow
$32,253K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Allocation of facilities and it ...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Compensation expense
Compensation expense
Others

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	139,071	140,636	376,509	-
Laboratory supplies and reagents expense	12,314	14,150	43,134	-
Sample collection expense	3,288	3,038	9,398	-
Compensation expense	9,804	6,705	17,906	-
Other cost	4,937	5,638	14,017	-
Allocation of facilities and it expenses	2,963	3,587	9,989	-
Cost of revenue-Testing	33,306	33,118	94,444	-
Product costs	1,401	1,923	1,864	-
License fees and royalties	313	318	888	-
Other cost	174	368	2,980	-
Allocation of facilities and it expenses	3	12	454	-
Cost of revenue-Product	1,891	2,621	6,186	-
Compensation expense	0	2	3,318	-
Other cost	8	215	3,118	-
Allocation of facilities and it expenses	0	0	925	-
Cost of revenue-Biopharmaceutical And Other	8	217	7,361	-
Intangible asset amortization - cost of revenue	2,707	2,707	7,959	-
Gross profit	101,159	101,973	260,559	-
Compensation expense	15,547	9,944	27,840	-
Direct expense	4,198	5,650	10,946	-
Other research and development expenses	5,460	3,214	5,278	-
Allocation of facilities and it expenses	1,893	2,041	5,901	-
Total research and development	27,098	20,849	49,965	-
Compensation expense	19,972	16,995	52,214	-
Direct expense	1,455	1,999	3,564	-
Other selling and marketing expenses	4,561	4,063	10,880	-
Allocation of facilities and it expenses	1,168	2,883	7,567	-
Total selling and marketing	27,156	25,940	74,225	-
Compensation expense	16,236	20,788	62,121	-
Other general and administrative expenses	13,471	5,102	56,132	-
Allocation of facilities and it expenses	-6,027	-8,523	-24,836	-
Total general and administrative	23,680	17,367	93,417	-
Impairment of assets	-	0	20,505	-
Intangible asset amortization - operating expenses-Intangible Asset Amortization	579	622	1,865	-
Other income, net	7,328	3,439	6,985	-
Income tax provision	1,267	-515	2,363	-
Net income	28,707	41,149	19,137	6,067
Depreciation and amortization	5,430	5,298	5,266	10,851
Loss on disposal of property, plant and equipment	-366	0	0	-15
Stock-based compensation	12,761	10,901	10,757	21,943
Deferred income taxes	-10	-568	-87	74
Noncash lease expense	732	702	689	1,600
Revaluation of acquisition-related contingent consideration	-350	-12,582	166	-2,879
Impairment loss	-	0	0	20,505
Non-cash loss on deconsolidation of subsidiary	-	-2,845	-3,863	-
Effect of foreign currency on operations	80	-11	-1,205	5,050
Supplies and inventory	-	219	-221	2,863
Amortization of discount on short-term investments	614	651	2,619	-
Accounts receivable	5,567	-3,150	-425	4,283
Supplies	870	-	-	-
Prepaid expenses and other current assets	1,306	-4,362	956	5,460
Other assets	132	-194	-1,720	1,389
Operating lease liabilities	-319	-799	-495	-1,186
Accounts payable	2,587	-492	-3,660	3,113
Accrued liabilities and deferred revenue	-6,120	-718	9,125	-2,091
Net cash provided by operating activities	35,215	52,583	44,757	38,967
Proceeds from sale of short-term investments	-	0	-	-
Proceeds from maturity of short-term investments	-	51,195	51,055	51,061
Loss on deconsolidation of subsidiary - cash	-	2,845	-	-
Acquisition of c2i, net of cash acquired	-	0	0	0
Purchase of short-term investments	124,999	50,000	0	99,998
Purchases of property, plant and equipment	2,962	3,780	2,792	3,105
Net cash used in investing activities	-127,961	-5,430	48,263	-52,042
Payment of contingent consideration for acquisition	-	0	-	-
Payment of taxes on vested restricted stock units	9,364	3,659	2,814	11,831
Proceeds from the exercise of common stock options and employee stock purchases	2,735	3,510	5,791	4,781
Net cash used in financing activities	-6,629	-149	2,977	-7,050
Decrease in cash, cash equivalents and restricted cash	-99,375	47,004	95,997	-20,125
Effect of foreign currency on cash, cash equivalents and restricted cash	-58	12	60	647
Net decrease in cash, cash equivalents and restricted cash	-99,433	47,016	96,057	-19,478
Cash, cash equivalents and restricted cash at beginning of period	364,226	317,210	240,631	-
Cash, cash equivalents and restricted cash at end of period	264,793	364,226	317,210	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

MyFinsight

Cash Flow Overview

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Cash Flow Overview

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow